Xtant Medical Holdings (XTNT) Cost of Revenue (2010 - 2025)

Xtant Medical Holdings (XTNT) has 16 years of Cost of Revenue data on file, last reported at $11.7 million in Q3 2025.

• Quarterly Cost of Revenue rose 1.0% year-over-year to $11.7 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $45.8 million (down 6.66% YoY) and the FY2024 annual result came in at $49.2 million, up 28.03% from the prior year.
• Cost of Revenue advanced to $11.7 million in Q3 2025 per XTNT's latest filing, from $11.1 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $13.6 million in Q4 2023 and bottomed at $4.9 million in Q1 2021.
• The 5-year median for Cost of Revenue is $8.7 million (2023), against an average of $8.9 million.
• The widest annual swing landed in 2021, when Cost of Revenue fell 24.29%; it then jumped 132.75% in 2023.
• Tracing XTNT's Cost of Revenue over 5 years: stood at $7.1 million in 2021, then decreased by 17.41% to $5.8 million in 2022, then jumped by 132.75% to $13.6 million in 2023, then slipped by 13.92% to $11.7 million in 2024, then climbed by 0.53% to $11.7 million in 2025.
• Per Business Quant, the three latest XTNT Cost of Revenue figures stand at $11.7 million (Q3 2025), $11.1 million (Q2 2025), and $11.2 million (Q1 2025).

Peer Comparison